Our Platform is Built for Scalability and Innovation


Native iNKT cells display intrinsic tumor targeting and killing potential for a wide range of tumors. However, certain cancers may not express sufficient natural iNKT ligands to be effectively killed, or may have a suppressive TME that limits the effectiveness of infiltrating iNKT cells. Adding a CAR, TCR or bispecific antibody-based cell engager can target specific cancer cells and enhance the potency and efficacy of iNKT cell therapy in a broader range of indications.